Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term double-blind extension trial of asenapine vs olanzapine in schizophrenia
2010-018408-96Phase 3Completed
- Sponsor
- Schering-Plough Research Institute
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of asenapine in schizophrenia (4 arms), sponsored by Schering-Plough Research Institute. Primary endpoint: Long-term safety of asenapine 2.5 mg and 5 mg BID. Started Jun 2013; status: completed.
02
Drugs
asenapine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2010-018408-96.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018408-96.